IN2014MN02213A - - Google Patents

Info

Publication number
IN2014MN02213A
IN2014MN02213A IN2213MUN2014A IN2014MN02213A IN 2014MN02213 A IN2014MN02213 A IN 2014MN02213A IN 2213MUN2014 A IN2213MUN2014 A IN 2213MUN2014A IN 2014MN02213 A IN2014MN02213 A IN 2014MN02213A
Authority
IN
India
Prior art keywords
formulations
incision
infiltration
api
administered
Prior art date
Application number
Other languages
English (en)
Inventor
Shimon Amselem
Michael Naveh
Original Assignee
Painreform Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Painreform Ltd filed Critical Painreform Ltd
Publication of IN2014MN02213A publication Critical patent/IN2014MN02213A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2213MUN2014 2012-05-10 2013-05-09 IN2014MN02213A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261645066P 2012-05-10 2012-05-10
US201261649400P 2012-05-21 2012-05-21
US201361781625P 2013-03-14 2013-03-14
US201361781595P 2013-03-14 2013-03-14
PCT/IL2013/050404 WO2013168167A1 (fr) 2012-05-10 2013-05-09 Préparations de dépôt d'un principe actif hydrophobe et procédés de préparation associés

Publications (1)

Publication Number Publication Date
IN2014MN02213A true IN2014MN02213A (fr) 2015-07-10

Family

ID=49550270

Family Applications (2)

Application Number Title Priority Date Filing Date
IN2213MUN2014 IN2014MN02213A (fr) 2012-05-10 2013-05-09
IN2214MUN2014 IN2014MN02214A (fr) 2012-05-10 2013-05-09

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN2214MUN2014 IN2014MN02214A (fr) 2012-05-10 2013-05-09

Country Status (9)

Country Link
US (3) US9668974B2 (fr)
EP (2) EP2846772A4 (fr)
JP (4) JP2015516412A (fr)
CN (2) CN104427976B (fr)
AU (2) AU2013257546B2 (fr)
CA (2) CA2871821C (fr)
IN (2) IN2014MN02213A (fr)
RU (2) RU2678433C2 (fr)
WO (2) WO2013168167A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104427976B (zh) * 2012-05-10 2018-04-24 佩因拉佛姆有限公司 疏水的活性成分的储库制剂及其制备方法
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US11224593B2 (en) * 2015-07-13 2022-01-18 Neon Laboratories Limited Hyperbaric injection solution of ropivacaine hydrochloride and process for preparation thereof
JP2020536955A (ja) 2017-10-06 2020-12-17 ファウンドリー セラピューティクス， インコーポレイテッド 治療剤の制御放出のための埋込み可能なデポー
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
WO2019226599A1 (fr) * 2018-05-22 2019-11-28 Alkalidx, Inc. Diagnostics et traitements de sujets insensibles à un anesthésique
CN109316602A (zh) * 2018-11-13 2019-02-12 西安力邦医药科技有限责任公司 一种长效镇痛并促进伤口愈合的复方缓释递药系统的组方与应用
JP7378929B2 (ja) * 2018-12-27 2023-11-14 花王株式会社 リポソームの製造方法
CN111388418B (zh) * 2018-12-31 2022-09-06 北京泰德制药股份有限公司 一种含有罗哌卡因或其药用盐的药物组合物
CN114007590A (zh) * 2019-06-28 2022-02-01 江苏恒瑞医药股份有限公司 一种缓释脂质组合物及其制备方法
CN113116813B (zh) * 2020-01-14 2022-11-29 中国科学院上海药物研究所 一种储库型罗哌卡因药物组合物及其制备方法和用途
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics
CN115463084B (zh) * 2021-06-10 2024-05-28 北京泰德制药股份有限公司 一种长效镇痛用复方油溶液制剂及其制备方法
GB202404399D0 (en) * 2021-09-15 2024-05-08 Ocusoft Inc Ointments for treating dry skin
US20240065995A1 (en) * 2022-08-27 2024-02-29 Darren Alexander Rubin Injectable methods to treat deficiencies in glutathione metabolism and homocystinuria

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252793A (en) 1979-06-18 1981-02-24 American Lecithin Company Injectable lecithin preparation
WO1995013796A1 (fr) 1993-11-16 1995-05-26 Depotech Corporation Vesicules a taux controle de liberation des principes actifs
JPH0753661B2 (ja) 1984-03-08 1995-06-07 フアレス フアーマスーチカル リサーチ エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
US5173219A (en) 1986-02-12 1992-12-22 Research Development Foundation Uniform spherical multilamellar liposomes of defined and adjustable size distribution
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
NZ223660A (en) 1987-03-05 1990-11-27 Liposome Co Inc Low toxicity drug-lipid complexes; methods of making them; and method of determining their toxicity
CH681427A5 (fr) 1987-07-01 1993-03-31 Zambon Spa
US5807572A (en) 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5576017A (en) 1988-05-30 1996-11-19 Depotech Corporation Heterovesicular liposomes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JP3571717B2 (ja) 1991-10-04 2004-09-29 ゲー・エス・デイベロツプメント・アクチエボラーグ 粒子、該粒子の製法及びその使用
SE9200952D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical carrier system containing defined lipids
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
EP1013270A3 (fr) 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Microsphères contenant une hormone de croissance à libération régulée
EP0695169B1 (fr) 1993-04-22 2002-11-20 SkyePharma Inc. Liposomes multivesiculaires de cyclodextrine encapsulant des composes pharmacologiques et leurs procedes d'utilisation
US5455044A (en) 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
SE9302218D0 (sv) 1993-06-28 1993-06-28 Ab Astra New use
CA2166465C (fr) * 1993-07-08 2003-10-14 Laura M. Edgerly-Pflug Methode de regulation de la taille des liposomes
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
NZ276088A (en) 1993-11-19 1999-07-29 Janssen Pharmaceutica Nv [(1,2-benzisoxazol-3-yl)-1-piperidinyl-alkyl-6,7,8,9-tetrahydro-4h- pyrido[1,2-a]-pyrimidin-4-one derivatives (ie risperidone)
US5635206A (en) * 1994-01-20 1997-06-03 Hoffmann-La Roche Inc. Process for liposomes or proliposomes
US5693337A (en) 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
HU223475B1 (hu) 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5981592A (en) 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6160018A (en) 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
JP4060884B2 (ja) * 1995-08-28 2008-03-12 昭和薬品化工株式会社 局所麻酔用組成物
ES2138130T3 (es) * 1995-10-28 2000-01-01 Braun Melsungen Ag Composicion farmaceutica que contiene un anestesico local y/o un analgesico de accion central.
US5744337A (en) 1995-12-26 1998-04-28 The United States Of America As Represented By The Secretary Of The Navy Internal gelation method for forming multilayer microspheres and product thereof
FR2753626B1 (fr) 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
GB2326337A (en) 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
US6306432B1 (en) 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
US6106858A (en) 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
ATE535232T1 (de) 1997-09-18 2011-12-15 Pacira Pharmaceuticals Inc Retardierte freisetzung liposomaler anesthetischer zusammensetzungen
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
AU1297899A (en) 1997-10-31 1999-05-24 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
JP4575592B2 (ja) 1997-11-14 2010-11-04 パシラ ファーマシューティカルズ インコーポレーテッド 多小胞リポソームの製造
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
DE69940735D1 (de) 1998-07-17 2009-05-28 Pacira Pharmaceuticals Inc Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen
ES2215277T3 (es) * 1998-08-18 2004-10-01 Panacea Biotec Limited Composicion de ciclosporina que comprende un vehiculo hidrofilo.
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
IL146567A0 (en) 1999-06-04 2002-07-25 Skyepharma Inc Oil-core particles containing a hydrophobic core material and hydrophobic drug and method for the preparation thereof
KR100343125B1 (ko) * 1999-09-14 2002-07-05 임정옥 도포용 리포좀형 혼합국소마취제 및 그 제조방법
EP1138313A1 (fr) 2000-03-28 2001-10-04 Primacare S.A. Proliposomes
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
IL139177A0 (en) 2000-10-20 2001-11-25 S C Republic Dev S R L Sustained release drug delivery system
JP2004532252A (ja) 2001-05-31 2004-10-21 スカイファーマ インコーポレーテッド リポソームおよびミクロスフェア中のナノ懸濁物のカプセル化
US20030099674A1 (en) 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
IL162213A0 (en) 2001-12-03 2005-11-20 Novacea Inc Pharmaceutical compositions containing active vitamin d compounds
WO2003086381A1 (fr) 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Formulations d'ansamycine et procedes de production et d'utilisation de celles-ci
US20030236306A1 (en) 2002-06-20 2003-12-25 Chen Andrew X. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US7229630B2 (en) 2002-06-20 2007-06-12 Novalar Pharmaceuticals, Inc. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
AU2003266159A1 (en) 2002-09-16 2004-04-30 Zicam, Llc. System and method for delivering a composition to the nasal membrane
US7074826B2 (en) 2002-10-07 2006-07-11 Encore Pharmaceuticals, Inc. R-NSAID esters and their use
US20050026877A1 (en) 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050049209A1 (en) 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US7968122B2 (en) 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
US20050186230A1 (en) 2004-01-23 2005-08-25 Sd Pharmaceuticals, Inc. Elemene compositions containing liquid oil
WO2005082382A1 (fr) 2004-02-23 2005-09-09 Attenuon Llc Formulations de composés de thiomolybdate ou de thiotungstate et leurs utilisations
DE602005008247D1 (de) 2004-06-04 2008-08-28 Camurus Ab Flüssige depotformulierungen
WO2006002050A1 (fr) 2004-06-15 2006-01-05 Encore Therapeutics, Inc. Compositions phospholipidiques, procede de fabrication et methode d'utilisation
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
RU2007107359A (ru) 2004-07-28 2008-09-10 ЭсДи ФАРМАСЬЮТИКАЛЗ, ИНК. (US) Стабильная инъецируемая композиция альфа-токоферилсукцината, его аналогов и солей
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
RU2008104638A (ru) 2005-07-07 2009-08-20 Фарнэм Компаниз, Инк. (Us) Фармацевтические композиции хорошо растворимых в воде лекарственных средств, обеспечивающих их замедленное высвобождение
WO2007041476A2 (fr) * 2005-09-30 2007-04-12 Vyteris, Inc. Indications pour le transport local d'agents anesthesiques par des dispositifs d' electrotransport
CN101321518A (zh) 2005-12-02 2008-12-10 阿德文特克斯药物有限公司 5,10-亚甲基四氢叶酸盐的稳定药物组合物
CN100518738C (zh) 2006-01-06 2009-07-29 中国药科大学 一种含喜树碱类药物的自组装前体脂质体及其制备方法
CN100563715C (zh) 2006-01-06 2009-12-02 中国药科大学 一种紫杉醇自组装前体脂质体及其制备方法
CN100486569C (zh) 2006-01-06 2009-05-13 中国药科大学 一种多烯紫杉醇自组装前体脂质体及其制备方法
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
AU2007351338B2 (en) * 2006-12-07 2013-04-04 Lyotropic Therapeutics, Inc. Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
EP1938801A1 (fr) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoémulsion
WO2008088756A1 (fr) * 2007-01-12 2008-07-24 Bridge Pharma, Inc. Compositions dermiques d'amides substituées et utilisation de celles-ci comme médication contre la douleur et le prurit
ES2350029T3 (es) 2007-03-02 2011-01-17 Farnam Companies, Inc. Pellets de liberación sostenida que comprenden un material tipo cera.
CA2681302C (fr) * 2007-03-19 2013-07-23 Dhiraj Khattar Compositions proliposomales et liposimale de composes faiblement hydrosolubles
BRPI0704542B8 (pt) 2007-05-15 2021-05-25 Univ Estadual Campinas Unicamp composição farmacêutica, processo de obtenção da composição farmacêutica, uso de uma quantidade farmaceuticamente eficaz de anestésico e agente gelificante, produto e método de tratamento
RU2429242C2 (ru) 2007-05-30 2011-09-20 Учреждение Российской Академии Наук Институт Проблем Химической Физики Ран (Ипхф Ран) Применение тетранитрозильного комплекса железа с тиофенолом в качестве противоопухолевого лекарственного средства
HUP0700426A2 (en) 2007-06-19 2010-03-29 Invencio 21 Gyogyhatasu Keszit Liposomal compound
US20100310661A1 (en) 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
FR2924024B1 (fr) 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
CN101485629B (zh) 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
CN102202654B (zh) 2008-09-04 2014-07-30 法纳姆公司 可咀嚼的缓释制剂
CA2738630A1 (fr) 2008-10-10 2010-04-15 Dara Biosciences, Inc. Methodes de traitement prophylactique ou therapeutique de la douleur a l'aide de derives de spicamycine
WO2010138918A1 (fr) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase comme adjuvant pour augmenter le volume d'injection et la dispersion de vésicules membranaires synthétiques de grand diamètre contenant un agent thérapeutique
EP2470019A4 (fr) 2009-08-25 2013-03-13 Cardiokine Biopharma Llc Compositions pour administrer des agents insolubles
WO2011075623A1 (fr) 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. Composition de gel à une phase comprenant des phospholipides
EP2336286A1 (fr) 2009-12-18 2011-06-22 The Procter & Gamble Company Composition comprenant des microcapsules
US8313766B2 (en) 2010-02-05 2012-11-20 Andrew Chen Oral antidepressant formulation with reduced excipient load
EP2552408A2 (fr) 2010-04-01 2013-02-06 Pharmanest AB Compositions pharmaceutiques sans eau appropriées à des anesthésiques locaux
EP3175844A1 (fr) 2010-04-09 2017-06-07 Pacira Pharmaceuticals, Inc. Vésicules membranaires synthétiques de grand diamètre
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
WO2011153513A2 (fr) 2010-06-03 2011-12-08 Latitude Pharma Composition de nano-émulsion contenant de la vitamine k
AU2011276552B2 (en) 2010-06-29 2015-09-03 Verastem, Inc. Oral formulation of kinase inhibitors
CN103052382B (zh) 2010-07-14 2014-10-22 千寿制药株式会社 α-酮酰胺衍生物的固体分散体
BR112013003934A2 (pt) 2010-08-20 2016-06-07 Reddys Lab Ltd Dr depot de fosfolipídeos
US20130203701A1 (en) 2010-09-17 2013-08-08 Maine Natural Health, Inc. Compositions containing omega-3 oil and uses thereof
KR101957177B1 (ko) 2010-10-22 2019-03-12 닥터 레디스 래보러토리즈 에스에이 상처를 치료하기 위한 저장 안정한 점성 인지질 데포의 용도
CN103260702B (zh) 2010-10-28 2018-07-27 帕西拉制药有限公司 非甾体类抗炎药的缓释制剂
EA201391821A1 (ru) 2011-06-09 2014-05-30 АМИЛИН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гелевые композиции
CN104427976B (zh) * 2012-05-10 2018-04-24 佩因拉佛姆有限公司 疏水的活性成分的储库制剂及其制备方法

Also Published As

Publication number Publication date
US20180049985A1 (en) 2018-02-22
IN2014MN02214A (fr) 2015-07-17
WO2013168172A1 (fr) 2013-11-14
AU2013257546A1 (en) 2014-11-27
JP2018035179A (ja) 2018-03-08
EP2846772A4 (fr) 2015-12-30
AU2013257608B2 (en) 2017-12-14
AU2013257608A1 (en) 2014-11-27
US9849088B2 (en) 2017-12-26
RU2014144501A (ru) 2016-07-10
JP2017222729A (ja) 2017-12-21
EP2846773A1 (fr) 2015-03-18
EP2846773A4 (fr) 2015-12-30
JP6574228B2 (ja) 2019-09-11
RU2678433C2 (ru) 2019-01-29
AU2013257546B2 (en) 2017-12-14
JP6577548B2 (ja) 2019-09-18
CA2871821A1 (fr) 2013-11-14
US20150148325A1 (en) 2015-05-28
WO2013168167A1 (fr) 2013-11-14
CA2871821C (fr) 2021-01-12
CN104427976A (zh) 2015-03-18
RU2664700C2 (ru) 2018-08-21
CN104427977B (zh) 2018-02-02
US9668974B2 (en) 2017-06-06
CN104427976B (zh) 2018-04-24
RU2014144500A (ru) 2016-07-10
CA2871820A1 (fr) 2013-11-14
CA2871820C (fr) 2020-11-03
EP2846772A1 (fr) 2015-03-18
JP2015516411A (ja) 2015-06-11
US20150111923A1 (en) 2015-04-23
CN104427977A (zh) 2015-03-18
US10206876B2 (en) 2019-02-19
JP2015516412A (ja) 2015-06-11

Similar Documents

Publication Publication Date Title
IN2014MN02213A (fr)
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
MX2021006035A (es) Formulaciones cannabinoides estables.
MX2016005395A (es) Formulacion estable de insulina glulisina.
PH12016500024A1 (en) Bromodomain inhibitor
EP4285928A3 (fr) Formulations d'anticorps anti-pdl1
MX2019003693A (es) Formulaciones de insulina de accion prolongada.
MX2014011181A (es) Microemulsiones basadas en ciclodextrina y usos dermatologicos de las mismas.
MX369121B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
MD20150050A2 (ro) Soluţii midriatice şi antiinflamatorii stabile fără conservanţi pentru injectare
MX2021010359A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
EP4360621A3 (fr) Formulations de bendamustine
IN2014MN01470A (fr)
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
PH12015502556A1 (en) Modified release formulation
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
EP2981258B8 (fr) Formulations pharmaceutiques pour l'administration sous-cutanée de furosémide
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
WO2013100869A3 (fr) Systèmes de nano-véhicules à base de lipide destiné à être utilisés pour le traitement contre le cancer
MX2016004328A (es) Inmunopotenciador.
BR112017019364A2 (pt) dispersões sólidas
IN2014DN09246A (fr)
GB201204632D0 (en) Delivery system
EP2668952A3 (fr) Formulations aqueuses de bisphosphonates, de vitamine D et d'alcool benzylique appropriées pour une utilisation sous-cutanée ou intramusculaire